Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Selumetinib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 17,197Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Koselugo Shows Improve in NF1 Plexiform Neurofibromas in Ph 3 Trial
    Koselugo Shows Improve in NF1 Plexiform Neurofibromas in Ph 3 Trial

    12 Nov 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241112487947/en

    BUSINESSWIRE
    12 Nov 2024
    Share Share
    China NMPA approves Koselugo for paediatric patients
    China NMPA approves Koselugo for paediatric patients

    08 May 2023

    // PHARMABIZ

    http://pharmabiz.com/NewsDetails.aspx?aid=158008&sid=2

    PHARMABIZ
    08 May 2023
    Share Share
    Koselugo approved in Japan for paediatric patients with plexiform neurofibromas
    Koselugo approved in Japan for paediatric patients with plexiform neurofibromas

    28 Sep 2022

    // PHARMABIZ

    http://www.pharmabiz.com/NewsDetails.aspx?aid=153495&sid=2

    PHARMABIZ
    28 Sep 2022
    Share Share
    AstraZeneca Pharma India gets nod to import, market Selumetinib capsules
    AstraZeneca Pharma India gets nod to import, market Selumetinib capsules

    26 Sep 2021

    // BUSINESS-STANDARD

    https://www.business-standard.com/article/companies/astrazeneca-pharma-india-gets-nod-to-import-market-selumetinib-capsules-121092600914_1.html

    BUSINESS-STANDARD
    26 Sep 2021
    Share Share
    AstraZeneca Pharma India gets nod to import, market Selumetinib capsules
    AstraZeneca Pharma India gets nod to import, market Selumetinib capsules

    25 Sep 2021

    // BUSINESS-STANDARD

    https://www.business-standard.com/article/companies/astrazeneca-pharma-india-gets-nod-to-import-market-selumetinib-capsules-121092600914_1.html

    BUSINESS-STANDARD
    25 Sep 2021
    Share Share
    Selumetinib recommended for approval in the EU by CHMP as the first medicine
    Selumetinib recommended for approval in the EU by CHMP as the first medicine

    26 Apr 2021

    // PRESS RELEASE

    https://www.astrazeneca.com/media-centre/press-releases/2021/selumetinib-recommended-for-eu-approval-in-nf1.html

    PRESS RELEASE
    26 Apr 2021
    Share Share